Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Christopher R. Franks"'
Autor:
Hubert Poliwoda, Jens Atzpodien, Tim Olivera, Peter A. Palmer, Hartmut Kirchner, Heiner Bodenstein, Christopher R. Franks, Peter de Mulder
Publikováno v:
Cancer Biotherapy. 8:289-300
A phase II multiinstitutional clinical trial was conducted to evaluate the safety and efficacy of the subcutaneous outpatient administration of recombinant human interleukin-2 and alpha-interferon in patients with progressive metastatic renal cell ca
Publikováno v:
Renal Failure. 15:195-201
Renal tubular function was evaluated in nine patients undergoing recombinant interleukin 2 (rIL2) treatment for metastatic colorectal carcinoma. A lithium clearance technique was used and the activities of the lysosomal enzyme N N-acetyl-beta-D-gluco
Autor:
Christopher R. Franks, Pauline Evers, Peter A. Palmer, Catherine N. Pourreau, Jan Vinke, Eveline Loriaux, Frans Vlems, Lisa Becker, R. Oskam, G. J. Roest
Publikováno v:
European Journal of Cancer. 28:1038-1044
Data have been analysed for 327 patients with advanced renal cell carcinoma receiving a continuous infusion of recombinant interleukin 2 (rIL-2) alone (225 patients) or rIL-2 plus lymphokine activated killer (LAK) cells (102) on a normal oncology war
Autor:
V. Mattijssen, Peter A. van Liessum, D. J. Theo Wagener, Frans H.M. Corstens, Christopher R. Franks, Pieter H.M. De Mulder
Publikováno v:
Cancer. 65:2686-2688
The development of transient hypothyroidism and goiter in a patient with a metastasized malignant melanoma during treatment with recombinant interleukin-2 (rIL-2) and dacarbazine is reported. Signs of autoimmune thyroiditis became apparent 2 weeks af
Autor:
Christopher R. Franks, Peter A. Palmer
Publikováno v:
The role of interleukin-2 in the treatment of cancer patients ISBN: 9789401047692
The clinical development of Interleukin-2 has been possible because the advent of biotechnology has resulted in the availability of unrestricted quantities of recombinant Interleukin-2 (rIL-2). Since there is little or no precedence, the initial inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8b04a5e4efd6d4f09a3b5800b6992d4
https://doi.org/10.1007/978-94-011-1753-1_10
https://doi.org/10.1007/978-94-011-1753-1_10
Autor:
R. Oskham, J.F. Cordier, P.A. Palmer, A. Mercatello, Christopher R. Franks, J.F. Moskovtchenko, J. Boyer, V. Trillet-Lenoir, J. Brune, Thierry Philip, F. Champel, Pierre-Jean Souquet, D. Arpin
Publikováno v:
European journal of cancer (Oxford, England : 1990). (13)
Autor:
T. Philip, J. Vinke, Hartmut Kirchner, Poul F. Geertsen, Jens Atzpodien, H. Von der Maase, Christopher R. Franks, P. Evers, R. Oskam, P.A. Palmer, E. Loriaux, G. J. Roest, Sylvie Negrier
Publikováno v:
Cancer biotherapy. 8(2)
To compare 2 treatment modalities with recombinant Interleukin-2 (rIL-2) for patients with advanced Renal Cell carcinoma (RCC): continuous intravenous infusion (CIV) alone versus subcutaneous (s/c) rIL-2 + Interferon-alpha (IFN-alpha).Data have been
Autor:
G. J. Roest, Zulma Gazit, Inna Kalichman, Hannah Ben-Bassat, Rut Isacson, Christopher R. Franks, Oded Yurim, Eitan Shiloni, Michael Schlesinger, Vivian Barak, Peter A. Palmer, S. Biran, Eli Kedar
Publikováno v:
Immunology letters. 33(2)
We have treated 18 patients with metastatic malignant melanoma (MM) with high-dose IL-2 administered by continuous iv infusion in combination with dacarbazine (DTIC), and correlated the clinical response with various hematologic and immunologic param
Autor:
R. Oskam, P.A. Palmer, Christopher R. Franks, W. Fiedler, P.H.M. de Mulder, C. Jasmin, D.K. Hossfeld, S. Pyrhönen
Publikováno v:
European journal of cancer (Oxford, England : 1990). 28(2-3)
16 patients with disseminated malignant melanoma (1 with primary ocular melanoma) entered a multicentre phase II study of recombinant interleukin-2, (rIL-2) given by continuous intravenous infusion on days 1–5 at 18 × 10 6 IU/m 2 per day, followed
Autor:
Simonetta Viviani, Giorgio Parmiani, Peter A. Palmer, Christopher R. Franks, Licia Rivoltini, Silvia Spinazzé, Franco Rovelli, Paolo Bidoli, Flavio Arienti
Publikováno v:
ResearcherID
Scopus-Elsevier
Scopus-Elsevier
Interleukin-2 has been shown to stimulate Cortisol secretion in man. Owing to its Immunosuppressive properties, an increase in Cortisol levels during interleukin-2 cancer immunotherapy could potentially counteract induced activation of the antitumor